Effects of adoptive T‐cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34716 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Akihiko Kida und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Public Central Hospital of Matto Ishikawa, Hakusan, Japan. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
The identification of immune cell profiles (ICP) involved in anti‐tumor immunity is crucial for immunotherapy. Therefore, we herein investigated cholangiocarcinoma patients (CCA) who received adoptive T‐cell immunotherapy (ATI). Eighteen unresectable or recurrent CCA received ATI of αβ T cells alone or combined with chemotherapy. ICP were evaluated by flow cytometry. There were 14 patients with intrahepatic cholangiocarcinoma (iCCA) and four with distal cholangiocarcinoma (dCCA). After one course of treatment, nine iCCA and four dCCA had progressive disease (PD), while five iCCA had stable disease (SD). Median overall survival (OS) was prolonged to 21.9 months. No significant differences were observed in OS between the PD and SD groups of iCCA. The frequency of helper T cells (HT) in iCCA decreased from 70.3% to 65.5% ( P = .008), while that of killer T cells (KT) increased from 27.0% to 30.6% ( P = .005). dCCA showed no significant changes of immune cells. OS was prolonged in iCCA with increased frequencies of CD3+ T cells (CD3) ( P = .039) and αβ T cells (αβ) ( P = .039). dCCA showed no immune cells associated with OS. The frequencies of CD3+ T cells and αβ T cells in the PD group for iCCA decreased from 63.5% to 53% ( P = .038) and from 61.6% to 52.2% ( P = .028), respectively. In the SD group, the frequency of HT decreased from 65.8% to 56.9% ( P = .043), whereas that of KT increased from 30.1% to 38.3% ( P = .043). In conclusions, ATI affected ICP and prolonged OS. Immune cells involved in treatment effects differed according to the site of cholangiocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Public Central Hospital of Matto Ishikawa, Hakusan, Japan.
- Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan.
- Department of Internal Medicine, Komatsu Sophia Hospital, Komatsu, Japan.
- Department of Surgical Oncology, Kanazawa Medical University, Kahoku-gun, Japan.
- Seta Clinic Group, Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
- Kanazawa Advanced Medical Center, Kanazawa, Japan.
ORCID-Profile: Akihiko Kida
Zitieren
APA
Kida, A., Mizukoshi, E., Kitahara, M., Miyashita, T., Goto, S., Kamigaki, T., Takimoto, R., Asai, J., Kakinoki, K., Urabe, T., Tomita, K., & Kaneko, S. (2024). Effects of adoptive T‐cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.34716
Vancouver
Kida A, Mizukoshi E, Kitahara M, Miyashita T, Goto S, Kamigaki T, et al. Effects of adoptive T‐cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma. International Journal of Cancer. 2024. doi:10.1002/ijc.34716
BibTeX
@article{Kida2024,
author = {Kida, Akihiko and Mizukoshi, Eishiro and Kitahara, Masaaki and Miyashita, Tomoharu and Goto, Shigenori and Kamigaki, Takashi and Takimoto, Rishu and Asai, Jun and Kakinoki, Kaheita and Urabe, Takeshi and Tomita, Katsuro and Kaneko, Shuichi},
title = {Effects of adoptive T‐cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34716}
}
EUVIMED